← Back to Screener
Nuvalent, Inc. Class A Common Stock (NUVL)
Price$90.95
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-24.75%
Price vs S&P 500 (4W)-13.60%
VGM Score50.29
Market Capitalization$7.18B
All Metrics
Book Value / Share (Quarterly)$14.89
P/TBV (Annual)8.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.97
Price vs S&P 500 (YTD)-17.74%
EPS (TTM)$-6.05
10-Day Avg Trading Volume1.13M
EPS Excl Extra (TTM)$-6.05
EPS (Annual)$-5.85
ROI (Annual)-34.08%
Cash / Share (Quarterly)$16.32
ROA (Last FY)-30.11%
EBITD / Share (TTM)$-5.90
ROE (5Y Avg)-22.08%
Cash Flow / Share (Annual)$-3.52
P/B Ratio6.12x
P/B Ratio (Quarterly)6.86x
Net Income / Employee (Annual)$-1,865,700
ROA (TTM)-37.79%
EPS Incl Extra (Annual)$-5.85
Current Ratio (Annual)15.27x
Quick Ratio (Quarterly)15.88x
3-Month Avg Trading Volume0.61M
52-Week Price Return16.47%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.93
52-Week High$113.02
EPS Excl Extra (Annual)$-5.85
26-Week Price Return-16.83%
Quick Ratio (Annual)15.05x
13-Week Price Return-9.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.14x
Enterprise Value$7.03B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$17.54
3-Month Return Std Dev44.68%
Net Income / Employee (TTM)$-1,974,000
ROE (Last FY)-34.08%
EPS Basic Excl Extra (Annual)$-5.85
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-6.05
ROI (TTM)-42.78%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.17
Price vs S&P 500 (52W)-7.90%
Year-to-Date Return-9.58%
5-Day Price Return-2.21%
EPS Normalized (Annual)$-5.85
ROA (5Y Avg)-20.58%
Month-to-Date Return-17.61%
Cash Flow / Share (TTM)$-2.03
EBITD / Share (Annual)$-5.70
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-22.08%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-6.05
P/TBV (Quarterly)10.01x
P/B Ratio (Annual)5.86x
Book Value / Share (Annual)$15.96
Price vs S&P 500 (13W)-17.42%
Beta1.22x
Revenue / Share (TTM)$0.00
ROE (TTM)-42.78%
52-Week Low$71.13
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.39est. -1.34
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.29
4.29
4.28
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NUVLNuvalent, Inc. Class A Common Stock | — | — | C | $90.95 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Nuvalent is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors for patients with genetically defined cancers. The company's pipeline includes NVL-520 for ROS1-positive NSCLC, NVL-655 for ALK-positive NSCLC, and NVL-330, a brain-penetrant HER2-selective inhibitor designed to address limitations of existing targeted therapies. All operations are based in the United States.